Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Theriva Biologics, Inc. on October 20, 2025. The company, incorporated in Nevada and headquartered in Rockville, Maryland, is an emerging growth company. The filing reports a significant clinical development event regarding its lead therapeutic candidate.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical trial update and does not contain financial statements or operational financial data.
Material Changes and Events
- Clinical Data Presentation: On October 20, 2025, expanded metastatic pancreatic ductal adenocarcinoma (mPDAC) data from the VIRAGE Phase 2b trial (NCT05673811) was presented.
- Event Venue: The data was presented during a mini oral session at the European Society for Medical Oncology (ESMO 2025) Annual Congress.
- Documentation: The full ESMO presentation is attached as Exhibit 99.1 and incorporated by reference.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on financial outlook, or a discussion of risks and contingencies beyond the standard incorporation of the clinical presentation. The primary focus is the dissemination of clinical trial results.
Investor Verification Checklist
- Review Exhibit 99.1 (ESMO presentation) for specific efficacy and safety data from the VIRAGE Phase 2b trial.
- Verify the clinical trial status and patient enrollment numbers for NCT05673811 on ClinicalTrials.gov.
- Assess the potential impact of the mPDAC data on future regulatory filings or partnership opportunities.
- Check subsequent filings for any financial updates or capital raise activities related to the trial results.